Overview
Egrifta.
FDA-approved peptide that shrinks belly (visceral) fat by triggering a GH pulse.
Has to be done at night on an empty stomach.
What It Does
FDA-approved GHRH analog (Egrifta), approved for HIV-associated lipodystrophy.
Full-length GHRH analog with a trans-3-hexenoic-acid modification.
Binds GHRH receptors for strong nightly GH pulses.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 5 mg | + 0.5 mL | 10 mg/mL |
| 10 mg | + 1 mL | 10 mg/mL |
| 20 mg | + 2 mL | 10 mg/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Protocol
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Weeks 1–16 (legacy) | Nightly | 2 mg | Original Egrifta clinical dose (no titration per label). Hold here for the full cycle. |
| Egrifta WR (2025) | Nightly | 1.28 mg | F8 weekly-reconstitution formulation dose. Same molecule and indication. |
| Off | 4–8 weeks | – | Pituitary and receptor recovery before re-cycling. |
Ongoing per FDA Egrifta label (continuous nightly for HIV lipodystrophy); off-label use sometimes cycles 12–16 wks on / 4–8 off with IGF-1 recheck.
Pre-bed nightly, fasted; no food 90 min before / 60 min after (food blunts GH response per label).
Women make ~3× the GH of men yet have similar IGF-1, they’re less responsive, so often need a higher dose to move IGF-1. Oral estrogen blunts IGF-1 further (read it as running low); a skin patch/gel is more predictable. Men: Men convert GH to IGF-1 more efficiently and more often overshoot the age ceiling (a higher malignancy signal), aim mid-normal for age, don’t chase the Women make ~3× the GH of men yet have similar IGF-1, they’re less responsive, so often need a higher dose to move IGF-1. Oral estrogen blunts IGF-1 further (read it as running low); a skin patch/gel is more predictable. Men: Men convert GH to IGF-1 more efficiently and more often overshoot the age ceiling (a higher malignancy signal), aim mid-normal for age, don’t chase the top.
Handling & Stacking
- Freeze-dried: -4°F.
- Reconstituted: 36–46°F.
- Its own label says inject soon after reconstituting and not to store the mixed drug, so treat potency as only days to ~2 weeks (structure-based estimate).
- Keep the cold chain.
- Visceral-fat reduction at 8–12 weeks.
- Strict night-only injection, food within 90 min blunts GH response significantly.
- Monitor fasting glucose.
- Supply math 5mg → 45 vials | 10mg → 23 | 20mg → 12 vials (16-wk @ 2 mg × 7/wk)
- Active malignancy (FDA-labelled contraindication, USPI).
- Severe diabetic retinopathy.
- Monitor IGF-1 elevation.
- MASH/NAFLD in non-HIV patients: strong off-label signal but NOT an approved indication.
Safety & Patient Education
- IGF-1 (baseline + Week 8 + end; hold/reduce if IGF-1 >350–400 ng/mL or above age-ULN), Fasting glucose (Week 0/4/8) + HbA1c, Lipid panel (Week 0/12), age-appropriate cancer screening before starting., Out of range?
- IGF-1 above your age range = too much growth signal (feeds hidden cancer, enlarges organs) → drop the dose; rising glucose/HbA1c = sugar creeping up.
- GH-axis stimulation is not appropriate during active malignancy or for fertility.
- Most GH pulses occur during deep sleep, dose pre-bed.
- Food within 90 min blunts the response.
- Report new lumps, persistent headaches, or vision changes immediately.
